mTOR and cancer therapy
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 2×
“The idea that tumors arise from a rare population of self-renewing cancer stem cells capable of generating a hierarchy of more differentiated cells with limited potential to replicate was first demonstrated in leukemia (Lapidot et al., 1994).”
BackgroundTSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Levine, B., & Klionsky, D. J. (2004) · Developmental Cell · doi:10.1016/s1534-5807(04)00099-1 · Cited by 3,678
Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy
Pattingre, S., Tassa, A., Qu, X., Garuti, R., Liang, X. H., Mizushima, N., Packer, M., Schneider, M. D., & Levine, B. (2005) · Cell · doi:10.1016/j.cell.2005.07.002 · Cited by 3,536
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347 · cited 1×
“…for this is provided in breast cancer in which one copy of the essential autophagy gene BECN1, which codes for the protein BECLIN 1, is frequently deleted, while the remaining copy of BECN1 is wild-type, indicating that BECLIN 1 may be acting as a haploinsufficent oncogene (Liang et al., 1999).”
Background
Cited by
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,006
Effects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast
Torres, E. M., Sokolsky, T., Tucker, C. M., Chan, L. Y., Boselli, M., Dunham, M. J., & Amon, A. (2007) · Science · doi:10.1126/science.1142210 · Cited by 935
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Bhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Azad, M. B., Chen, Y., & Gibson, S. B. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2270 · Cited by 760
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
“In clinical studies, these compounds have been shown to be effective against many types of cancers (Easton and Houghton, 2006; Faivre et al., 2006).”
BackgroundSignalling to translation: How signal transduction pathways control the protein synthetic machinery
Proud, C. G. (2007) · Biochemical Journal · doi:10.1042/bj20070024 · Cited by 520
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Mitogenic signaling pathways induced by G protein‐coupled receptors
Rozengurt, E. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21246 · Cited by 460
Rapamycin and mTOR kinase inhibitors
Ballou, L. M., & Lin, R. Z. (2008) · Journal of Chemical Biology · doi:10.1007/s12154-008-0003-5 · Cited by 442
MicroRNA-451 Regulates LKB1/AMPK Signaling and Allows Adaptation to Metabolic Stress in Glioma Cells
Godlewski, J., Nowicki, M. O., Bronisz, A., Nuovo, G., Palatini, J., De Lay, M., Van Brocklyn, J., Ostrowski, M. C., Chiocca, E. A., & Lawler, S. E. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.018 · Cited by 419
Autophagy in Atherosclerosis: A Cell Survival and Death Phenomenon With Therapeutic Potential
Martinet, W., & De Meyer, G. R. Y. (2009) · Circulation Research · doi:10.1161/circresaha.108.188318 · Cited by 381
Rare cancer-specific mutations in PIK3CA show gain of function
Gymnopoulos, M., Elsliger, M.-A., & Vogt, P. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701005104 · Cited by 376
Common corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
Autophagy as a therapeutic target in cancer
Chen, N., & Karantza, V. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14622 · Cited by 303
Wang, X., Pan, C., Gong, J., Liu, X., & Li, H. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00690 · Cited by 290
Therapy for Osteosarcoma: Where Do We Go From Here?
Chou, A. J., Geller, D. S., & Gorlick, R. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 274
Molinolo, A. A., Hewitt, S. M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., Meneses García, A., Raimondi, A. R., Jufe, R., Itoiz, M., Gao, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1041 · Cited by 243
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194
“Nonetheless, rapamycin strongly affects cell proliferation, cell growth and angiogenesis (Averous and Proud, 2006; Easton and Houghton, 2006; Mamane et al., 2006; Sabatini, 2006).”
InfluentialLee, H., Kim, J.-S., & Kim, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050624 · Cited by 191
“The dysregulation of mTOR pathway can be observed in human diseases, especially certain cancers, and there are also some mTOR inhibitors, which are beginning to be used in the treatment of cancer [22].”
BackgroundCaccamo, A., Majumder, S., Deng, J. J., Bai, Y., Thornton, F. B., & Oddo, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031278 · Cited by 169
Translation Inhibitor Pdcd4 Is Targeted for Degradation during Tumor Promotion
Schmid, T., Jansen, A. P., Baker, A. R., Hegamyer, G., Hagan, J. P., & Colburn, N. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1719 · Cited by 151
“Moreover, inhibition of translation by mammalian target of rapamycin (mTOR) inhibitors is a promising and widely explored approach for cancer therapies (4).”
BackgroundTomek, K., Wagner, R., Varga, F., Singer, C. F., Karlic, H., & Grunt, T. W. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0467 · Cited by 64
Control of HIF-1α Expression by eIF2α Phosphorylation–Mediated Translational Repression
Zhu, K., Chan, W., Heymach, J., Wilkinson, M., & McConkey, D. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4103 · Cited by 55
Basal autophagy induction without AMP-activated protein kinase under low glucose conditions
Williams, T., Forsberg, L. J., Viollet, B., & Brenman, J. E. (2009) · Autophagy · doi:10.4161/auto.5.8.10090 · Cited by 42
Autophagy and its implication in Chinese hamster ovary cell culture
Kim, Y. J., Baek, E., Lee, J. S., & Lee, G. M. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1276-5 · Cited by 40
“Everolimus (RAD001) mTORC1 inhibitor Easton and Houghton (2006)”
BackgroundMulti-timescale dynamics study of FKBP12 along the rapamycin–mTOR binding coordinate
Sapienza, P. J., Mauldin, R. V., & Lee, A. L. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.10.037 · Cited by 32
Activated mTOR/P70S6K Signaling Pathway Is Involved in Insulinoma Tumorigenesis
Zhan, H., Cong, L., Zhao, Y., Zhang, T., Chen, G., Zhou, L., & Guo, J. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23176 · Cited by 18
“More and more studies had confirmed that activation of mTOR its downstream protein P70S6K played a significant role in tumor carcinogenesis in many human cancers [7,8].”
Background
Metadata
- Authors
- Easton, J. B., & Houghton, P. J.
- Venue
- Oncogene
- Published
- 2006-10-16
- Volume
- 25
- Issue
- 48
- Pages
- 6436-6446
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1988184140
- Cited by
- 459
- References
- 86
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.